期刊文献+

生物标志物与心血管疾病危险评估 被引量:3

暂未订购
导出
摘要 目前,越来越多的针对心血管疾病(CVD)的生物标志物不断被发现与研究。本文对与CVD危险评估相关的新生物标志物特别是炎症因子、纤溶相关蛋白、脂蛋白及其亚型、肾功能标志物及microRNAs等的临床应用进展进行简述。以期缩小CVD诊断的窗口期、发现更好的方法来指导治疗和评估预后。
作者 郑芳 鄢盛恺
出处 《临床检验杂志》 CAS CSCD 北大核心 2013年第5期321-323,共3页 Chinese Journal of Clinical Laboratory Science
  • 相关文献

参考文献10

二级参考文献107

  • 1鄢盛恺,陈文祥.临床血脂测定的方法学与标准化进展[J].中华心血管病杂志,2004,32(11):1050-1053. 被引量:10
  • 2许贤林,叶启发,何小舟,张晓膺,罗光华,朱江,Ning Xu,巢志复.缺血再灌注损伤对载脂蛋白M表达的影响[J].苏州大学学报(医学版),2005,25(3):402-404. 被引量:1
  • 3中国成人血脂异常防治指南[J].中华心血管病杂志,2007,35(5):390-419. 被引量:5235
  • 4Ensign W, Hill N, Heward CB. Disparate LDL phenotypie classifi- cation among 4 different methods assessing LDL particle characteris- tics[J]. Clin Chem, 2006,52(9) :1722-1727.
  • 5Hirano T, ho Y, Yoshino G. Measurement of small dense low-densi- ty lipoprotein particles [ J ]. J Atheroseler Thromb, 2005, 12 (2) : 67-72.
  • 6Ito Y, Fujimura M, Ohta M, et al. Development of a homogeneous assay for t of small dense LDL cholesterol [ J ]. Clin Chem, 2011, 57(1):57-65.
  • 7Mallol R, Rodriguez MA, Heras M, et al. Particle size measurement of lipoprotein fractions using diffusion-ordered NMR spectroscopy [J]. Anal Bioanal Chem, 2012, 402(7) :2407-2415.
  • 8Cromwell WC, Otvos JD, Keyes MJ, et al. LDL particle number andrisk of future cardiovascular disease in the Framingham Offspring Study-implications for LDL management [ J ]. J Clin Lipidology, 2007, 1 (6) :583-592.
  • 9Otvos JD, Mora S, Shalaurova I, et al. Clinical implications of dis- cordance between low-density lipoprotein cholesterol and particle number[J].J Clin Lipidology, 2011, 5(2) :105-113.
  • 10Brunzell JD, Davidson M, Furberg CD, et al. Lipoprotein manage- ment in patients with cardiometabolic risk : consensus statement from the American Diabetes Association and the American College of Car- diology Foundation [ J ]. Diabetes Care, 2008,31 (4) : 811-822.

共引文献40

同被引文献23

  • 1吴健,王玉,陈双叶.降钙素原与危重症患者预后的相关性研究[J].实用药物与临床,2007,10(2):77-78. 被引量:7
  • 2Johnson JL, Devel L, Czarny B, et al. A selective matrix metal- loproteinase-12 inhibitor retards atherosclerotic plaque develop- ment in apolipoprotein E-knockout mice [J]. Arteriosclerosis, Thrombosis, and Vascular Biology, 2011, 31(3): 528-535.
  • 3Trivedi V, Boire A, Tchernychev B, et al. Platelet matrix metal- loprotease-1 mediates thrombogenesis by activating PAR1 at a cryptic ligand site[J]. Cell, 2009, 137(2): 332-343.
  • 4Cavusoglu E, Marmur JD, Hegde S, et al. Relation of baseline plasma MMP-1 levels to long-term all-cause mortality in pa- tients with known or suspected coronary artery disease referred for coronary angiography[J]. Atherosclerosis, 2015, 239(1): 268-275.
  • 5Shin DH, Diet U, Melendez JA, et al. Regulation of MMP-1 ex- pression in response to hypoxia is dependent on the intracellularredox status of metastatic bladder cancer cells[J]. Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease, 2015, 1852(1 2593-2602.
  • 6Elkington P, Shiomi T, Breen R, et al. MMP-1 drives im- munopathology in human tuberculosis and transgenic mice [J]. The Journal of Clinical Investigation, 2011, 121(5): 1827-1831.
  • 7Wang F, Fisher J, Fishman DA. MMP-1-PAR1 axis mediates LPA-induced epithelial ovarian cancer (EOC) invasion[J]. Gyne- cologic Oncology, 2011, 120(2): 247-255.
  • 8Sch ti tz A, Rtiser K, Klitzsch J, et al. Lung adenocarcinomas and lung cancer cell lines show association of MMP-1 expres- sion with STAT3 activation[J]. Translational oncalogy, 2015, 8(2): 97-105.
  • 9Lin BC, Du X, Wang QR, et al. MMP-1 and pro-MMP-10 as potential urinary pharmacodynamic biomarkers of FGFR3-targeted therapy in patients with bladder cancer[J]. Cancer Research, 2014, 20(24): 6324-6335.
  • 10Weiss MB, Abel V, Mayberry MM, et al. TWIST1 is an ERK1/2 effector that promotes invasion and regulates MMP-1 expression in human melanoma cells[J]. Cancer Research, 2012, 72(24): 6382-6392.

引证文献3

二级引证文献13

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部